CD8A and neoplasm: Oncolytic immunotherapy has been shown to release a wide range of damage-associated molecular patterns (DAMP) and tumor-associated antigens (TAA) from whole tumor cells through oncolytic virus replication that would be taken up and cross-presented to CD8 + CTL T cells by activated dendritic cells, consequently leading to the activation of a tumor-targeting immune response [22].